RNA-based therapy for aging-associated diseases and Lifespan extension: LncRNA PRLB  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging, via down-regulation of its target gene, 15/January/2019, 11.58 pm

Natural product-based anti-ageing and Lifespan extension therapy:  A pharmaceutical mixture encompassing Celecoxib and quercetin (CQ) increases CHIP levels, increases monoubiquitylation of insulin receptor (INSR), decreases INSR protein levels and enhances lifespan, via down regulation of its target gene, 15/January/2019, 11.47 pm
January 15, 2019
Urine-derived compound functions as a longevity promoter: Ulinastatin (trade name: Miraclid, Ulinase, U-Tryp,Bikunin and Urinastatin), a trypsin inhibitor found in human urine and used in the treatment of  acute/chronic pancreatitis, burns and others, slows down cardiac aging, and increases lifespan, via up-regulation of BubR1 and others genes, 16/January/2019, 12.51 am
January 15, 2019
Show all

Introduction: What they say

A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and Department of Pharmacology, School of Medical Sciences, The University of New South Wales, Sydney, New South Wales 2052, Australia shows that “A conserved NAD+ binding pocket that regulates protein-protein interactions during aging.” This research paper was published, in the 24 March 2017 issue of the journal “Science [One of the best research journals in Science with an I.F of 34+], by Prof. David A. Sinclair, Jun Li and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: RNA-based therapy for aging-associated diseases and Lifespan extension: LncRNA PRLB  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging, via down-regulation of its target gene


What is known?

Prof. David A. Sinclair’s research team has recently shown that: (a) increased levels of NAD+ (found in non-aged tissues) inhibits the interaction the between DBC1 (deleted in breast cancer 1) and PARP1 [poly(adenosine diphosphate–ribose) polymerase]; and promotes DNA repair; (b) decreased levels of NAD+ (found in aged tissues) promotes the interaction between DBC1 and PARP1 and inhibits DNA repair; (c) aged cells/tissues that are low in NAD+ are radiation-sensitive, cancer-prone and prone to accelerated aging; and (d) aging-associated diseases can be reversed by increasing the concentration of NAD+ in aging tissues, suggesting that aging-associated diseases, in part, can be reversed by NAD+ supplementation in older animals.


From research findings to therapeutic opportunity:

This study suggests an RNA-based therapy for both aging-associated diseases, and life-span extension. LncRNA PRLB, by decreasing the expression of its target gene, it may increase the levels of NAMPT and NMN/NAD+. Thereby, it may: (1) increase plasma NMN levels and tissue NAD+ availability; (2) inhibit the interaction between DBC1 and PARP1; (3) augment PARP1’s DNA repair activity; (4) protect against radiation; (5) protect against cancer; and (6) prevent age-associated gene expression pattern and accelerated ageing. Thus, pharmacological formulations encompassing “LncRNA PRLB or its activators, either alone or in combination with other compounds,” may be used to suppress age-associated overall physiological decline and improve health/lifespan.[easy_payment currency=”USD”]

Figure1. LncRNA PRLB may act as an anti-aging and a longevity-promoting agent. LncRNA BRM, by increasing NAD+ levels, may suppress aging-associated overall physiological decline, aging-associated diseases and improve health/lifespan

Figure 2. LncRNA PRLB promotes health/life-span.


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does LncRNA PRLB increase the levels of NMN/NAD?

Amount: $300#

* Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Citation: Boominathan, L., RNA-based therapy for aging-associated diseases and Lifespan extension: LncRNA PRLB  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging, via down-regulation of its target gene, 15/January/2019, 11.58 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite us, kindly drop us a line

Comments are closed.